Dyne Therapeutics Conference Call Set for Topline Results
Dyne Therapeutics, Inc. (Nasdaq: DYN), a pioneering company dedicated to enhancing the lives of individuals affected by genetically driven neuromuscular diseases, is thrilled to announce that it will share results from the Registrational Expansion Cohort (REC) of its Phase 1/2 DELIVER clinical trial focusing on zeleciment rostudirsen (also referred to as DYNE-251). The event is scheduled for tomorrow, featuring a webcast that will begin at 8:00 a.m. ET.
What to Expect During the Webcast
The upcoming conference call will provide an opportunity for investors and stakeholders to gain insights into the topline clinical outcomes of Dyne’s promising trial. This presentation will be accessible via the Events & Presentations section of Dyne's website. Additionally, a replay of the webcast will be available for 90 days following the live event, ensuring that interested parties can catch up on this significant announcement.
Accessing the Webcast
To view the live session and the replay, attendees can visit Dyne's official events page. The company has also prepared a detailed slide presentation to accompany the session, enhancing the viewer experience and providing a clearer understanding of the data presented.
Insight into Dyne Therapeutics
At the core of Dyne Therapeutics' mission is the commitment to improve the functionality of individuals living with neuromuscular diseases. The company is breaking new ground with therapeutics designed to address muscle and central nervous system (CNS) challenges, targeting the underlying causes of these medical conditions. Their ongoing clinical efforts include advancements in treatments for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), alongside promising preclinical studies for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.
Commitment to the Community
Dyne’s dedication goes beyond just treatment. The organization aims to enhance the overall quality of life for affected individuals, their families, and communities by offering real solutions to these often debilitating conditions. This mission is what drives the team at Dyne to innovate continuously, striving to deliver the best possible results through their therapies.
Contact Dyne Therapeutics for More Information
For those interested in learning more about the developments at Dyne Therapeutics, several resources are available. The company encourages everyone to visit their website dedicated to investors, where they can find not only the upcoming events but also various informative reports outlining their clinical findings and updates.
Investor Contacts
Mia Tobias is the primary point of contact within Dyne for investor relations. She can be reached at ir@dyne-tx.com or by phone at 781-317-0353. For media inquiries, you can connect with Stacy Nartker at snartker@dyne-tx.com or call 781-317-1938.
Frequently Asked Questions
What is the focus of Dyne Therapeutics?
Dyne Therapeutics specializes in developing treatments for genetically driven neuromuscular diseases, aiming for functional improvements for those affected.
When will the webcast on the topline results be held?
The conference call is scheduled for December 8 at 8:00 a.m. ET.
How can the public access the webcast?
The webcast will be available on the Events & Presentations page on Dyne's website, along with a replay for 90 days afterward.
What clinical trials is Dyne currently involved in?
Dyne is actively conducting clinical trials for conditions such as Duchenne muscular dystrophy and myotonic dystrophy type 1.
Who can I contact for more information?
For investor inquiries, Mia Tobias can be contacted via email at ir@dyne-tx.com, and for media inquiries, reach out to Stacy Nartker at snartker@dyne-tx.com.
